Cell Pathways And Squibb Agree Joint Study

Cell Pathways, Inc. and Bristol-Myers Squibb Company plan to cooperate in supporting a clinical trial to study the combination of Aptosyn (exisulind) and TAXOL (paclitaxel) plus Paraplatin (carboplatin) as a first-line treatment for patients with advanced non- small cell lung cancer (NSCLC). This Phase I/II study is designed to evaluate escalating doses of Aptosyn in Read more about Cell Pathways And Squibb Agree Joint Study[…]

abbott laboratories

Idun And Abbott Extend Partnership Agreement

Idun Pharmaceuticals, Inc. has extended their worldwide research and development agreement with Abbott Laboratories focusing on the discovery and development of products to treat people with cancer. Under this agreement, Abbott and Idun will continue their collaboration to discover drugs that regulate the activity of specific proteins involved in the cell pathways leading to programmed Read more about Idun And Abbott Extend Partnership Agreement[…]

Biopulse Acquires Cancer Vaccine

BioPulse International, Inc. has acquired a new and improved method of creating dendritic cell cancer vaccines. “Antigens associated with cancerous tumours are not normally recognized by the immune system. With dendritic cell therapy, we’re teaching the dendritic cells to recognize the cancer antigens,” explains Dr. Robert Morrow, Director of Clinical Research for BioPulse. If the Read more about Biopulse Acquires Cancer Vaccine[…]

Diagnostic Products And Minerva Sign Development Agreement

Diagnostic Products Corp. and Minerva Pharmaceuticals Inc. have entered into a license agreement for the development of immunoassays for a newly described malignancy protein. Minerva Pharmaceuticals is a privately held Baltimore-based company formed for the purpose of commercialising platform technology licensed from the University of Maryland. Minerva founding scientists discovered that altered components of the Read more about Diagnostic Products And Minerva Sign Development Agreement[…]

Applied Imaging And Rigshospitalet University Agree Collaboration

Applied Imaging Corp. has teamed with Drs. Hans Skovgaard Poulsen and Jens Benn Sorensen from the Department of Oncology at the Rigshospitalet University of Copenhagen, Denmark, to optimize and validate a new blood test for the early diagnosis of cancer metastasis. The initial study will focus on patients suffering from colorectal tumors of all stages Read more about Applied Imaging And Rigshospitalet University Agree Collaboration[…]

imclone systems incorporated

ImClone And DAKO To Develop Screening Kit

ImClone Systems Incorporated and DAKO Corporation have entered into an agreement for the development of an Epidermal Growth Factor receptor (EGFr) screening kit. EGFr is a receptor associated with tumor cell growth in a number of solid tumors. The kit, to be developed by DAKO, will screen patients’ tumors for over-expression of EGFr as a Read more about ImClone And DAKO To Develop Screening Kit[…]

Progenics And Cytogen Announce Progress On Vaccine And Antibody Therapies For Prostate Cancer

Progenics Pharmaceuticals, Inc. and Cytogen Corporation have announced new findings on immune therapies which may play a future role in the treatment of prostate and other cancers. The therapies are directed against Prostate Specific Membrane Antigen (PSMA), a molecular cancer marker that is abundantly expressed on the surface of prostate cancer cells. The developments, presented Read more about Progenics And Cytogen Announce Progress On Vaccine And Antibody Therapies For Prostate Cancer[…]

Curagen And Gemini Enter Genome Wide Drug Target Discovery And Pharmacogenetics Collaboration

CuraGen Corporation, an integrated genomics based drug discovery and development company, and Gemini Genomics plc, announced today the largest collaboration to date linking cSNPs (human genetic variations) and clinical information to identify and validate novel drug targets for use in the discovery and development of pharmaceutical and diagnostic products. Specifically, CuraGen and Gemini scientists will Read more about Curagen And Gemini Enter Genome Wide Drug Target Discovery And Pharmacogenetics Collaboration[…]

Nutraceutix Licenses Subsidiary Of Boehringer-ingelheim To Market Calcium D-glucarate

Nutraceutix, Inc. has licensed Quest Vitamins, a subsidiary of Boehringer-Ingelheim, (Canada) Ltd. the non-exclusive right to distribute health supplement products containing the patented dietary supplement compound, Calcium D-Glucarate(TM). Boehringer Ingelheim group, is one of the world’s 20 leading pharmaceutical corporations — with products focused on human pharmaceuticals (prescription, hospital and self-medication) as well as animal Read more about Nutraceutix Licenses Subsidiary Of Boehringer-ingelheim To Market Calcium D-glucarate[…]

Antisoma Adopts Therex From Imperial Cancer Research Fund

Antisoma PLC has adopted a new clinical programme around Therex, a product based on the humanised monoclonal antibody huHMFG1 aiming to treat breast cancer. Originally developed by the Imperial Cancer Research Fund (ICRF), Therex is in a Phase I clinical study. The antibody targets most common epithelial cancers, including breast, lung, ovarian, gastric and colorectal Read more about Antisoma Adopts Therex From Imperial Cancer Research Fund[…]